Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3)
Journal of the American Academy of Dermatology | Sep 20, 2017
Psoriasis and suicidality: A systematic review and meta-analysis
Journal of the American Academy of Dermatology | Sep 19, 2017
|Serious infections among a large cohort of subjects with systemically treated psoriasis
Journal of the American Academy of Dermatology | Sep 19, 2017
Uncovering burden disparity: A comparative analysis of the impact of moderate-to-severe psoriasis and Hidradenitis suppurativa
Journal of the American Academy of Dermatology | Sep 18, 2017